☰

Helen N. Ha, Ph.D. - Publications

Affiliations: 
2013 Pharmacy/Pharmaceutical Sciences University of Southern California, Los Angeles, CA, United States 
Area:
Pharmacy
Tree Info Similar researchers PubMed Report error

8 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2017 Ha H, Debnath B, Neamati N. Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases. Theranostics. 7: 1543-1588. PMID 28529637 DOI: 10.7150/Thno.15625  0.569
2015 Ha H, Debnath B, Odde S, Bensman T, Ho H, Beringer PM, Neamati N. Discovery of Novel CXCR2 Inhibitors Using Ligand-Based Pharmacophore Models. Journal of Chemical Information and Modeling. 55: 1720-38. PMID 26153616 DOI: 10.1021/Acs.Jcim.5B00181  0.612
2014 Ha H, Neamati N. Pyrimidine-based compounds modulate CXCR2-mediated signaling and receptor turnover. Molecular Pharmaceutics. 11: 2431-41. PMID 24896229 DOI: 10.1021/Mp500180E  0.615
2014 Ha H, Bensman T, Ho H, Beringer PM, Neamati N. A novel phenylcyclohex-1-enecarbothioamide derivative inhibits CXCL8-mediated chemotaxis through selective regulation of CXCR2-mediated signalling. British Journal of Pharmacology. 171: 1551-65. PMID 24354854 DOI: 10.1111/Bph.12547  0.606
2013 Sangthong S, Ha H, Teerawattananon T, Ngamrojanavanich N, Neamati N, Muangsin N. Overcoming doxorubicin-resistance in the NCI/ADR-RES model cancer cell line by novel anthracene-9,10-dione derivatives. Bioorganic & Medicinal Chemistry Letters. 23: 6156-60. PMID 24095089 DOI: 10.1016/J.Bmcl.2013.09.004  0.475
2013 Ha H, Neamati N. Abstract 4558: Discovery and mechanistic studies of novel class of CXCR2 inhibitors. Cancer Research. 73: 4558-4558. DOI: 10.1158/1538-7445.Am2013-4558  0.615
2012 Aboye TL, Ha H, Majumder S, Christ F, Debyser Z, Shekhtman A, Neamati N, Camarero JA. Design of a novel cyclotide-based CXCR4 antagonist with anti-human immunodeficiency virus (HIV)-1 activity. Journal of Medicinal Chemistry. 55: 10729-34. PMID 23151033 DOI: 10.1021/Jm301468K  0.493
2009 Haiman CA, Garcia RR, Hsu C, Xia L, Ha H, Sheng X, Le Marchand L, Kolonel LN, Henderson BE, Stallcup MR, Greene GL, Press MF. Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: The Multiethnic Cohort Bmc Cancer. 9. PMID 19183483 DOI: 10.1186/1471-2407-9-43  0.311
Show low-probability matches.